RM Global closes USD 64m Biopharma investment fund.

BANKING AND CREDIT NEWS-April 12, 2019-RM Global closes USD 64m Biopharma investment fund

(C)2019 M2 COMMUNICATIONS http://www.m2.com

RMG Global has announced the final closing of completed the final closing of USD 64 million Israel-based RMGP Biopharma Investment Fund, adding investors from South Korea, the US, Europe and Israel, the company said.

The closing continues the strategic collaboration of RMG, the fund's manager, with the FutuRx Biopharma incubator and its partners, OrbiMed Israel, Johnson & Johnson Innovation, and Takeda Ventures, who jointly established FutuRx in cooperation with the Israel Innovation Authority (IIA).

The additional capital raised in this closing round, which together with prior closings represents USD 64 million in aggregate fund commitments, will continue to support the development of biotherapeutics in areas including oncology, CNS, orphan diseases and others.

The RMGP Biopharma...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT